- Home
- IOT vs BIIB Comparison
IOT vs BIIB Comparison
Compare IOT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOT
- BIIB
- Stock Information
- Founded
- IOT 2015
- BIIB 1978
- Country
- IOT United States
- BIIB United States
- Employees
- IOT N/A
- BIIB 7570
- Industry
- IOT Retail: Computer Software & Peripheral Equipment
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- IOT Technology
- BIIB Health Care
- Exchange
- IOT Nasdaq
- BIIB Nasdaq
- Market Cap
- IOT 25.6B
- BIIB 20.5B
- IPO Year
- IOT 2021
- BIIB 1991
- Fundamental
- Price
- IOT $46.86
- BIIB $140.55
- Analyst Decision
- IOT Buy
- BIIB Buy
- Analyst Count
- IOT 14
- BIIB 26
- Target Price
- IOT $50.86
- BIIB $234.79
- AVG Volume (30 Days)
- IOT 2.9M
- BIIB 1.4M
- Earning Date
- IOT 03-06-2025
- BIIB 02-11-2025
- Dividend Yield
- IOT N/A
- BIIB N/A
- EPS Growth
- IOT N/A
- BIIB 10.05
- EPS
- IOT N/A
- BIIB 11.06
- Revenue
- IOT $1,179,183,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- IOT $33.46
- BIIB N/A
- Revenue Next Year
- IOT $23.26
- BIIB N/A
- P/E Ratio
- IOT N/A
- BIIB $12.71
- Revenue Growth
- IOT 39.11
- BIIB N/A
- 52 Week Low
- IOT $27.14
- BIIB $140.05
- 52 Week High
- IOT $57.51
- BIIB $252.17
- Technical
- Relative Strength Index (RSI)
- IOT 53.60
- BIIB 29.25
- Support Level
- IOT $42.36
- BIIB $140.05
- Resistance Level
- IOT $46.78
- BIIB $150.48
- Average True Range (ATR)
- IOT 1.54
- BIIB 3.66
- MACD
- IOT 0.49
- BIIB -0.59
- Stochastic Oscillator
- IOT 100.00
- BIIB 3.06
About IOT Samsara Inc.
Samsara Inc provides an end-to-end solution for operations: The solution connects physical operations data to the Connected Operations Cloud, which consists of the Data Platform and Application. Geographically, it derives a majority of its revenue from the United States.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.